The FDA just cleared the first AI that reads burn wounds.

Run time: 20:51

In today's episode:

1. FDA grants De Novo clearance to burn-reading AI
2. Eli Lilly puts five hundred million into Korean AI lab
3. QIAGEN and NVIDIA team up on AI drug discovery
4. Bristol Myers Squibb rolls Claude to thirty thousand staff
5. Abu Dhabi and J&J launch AI surgical network
6. Artera takes multimodal cancer AI to ASCO
7. Twin Health launches AI for GLP-1 stewardship
8. Lancet study: ChatGPT discharge summaries boost patients
9. Claude adds twenty-eight security and compliance tools
10. DeepMind hires twenty researchers from Contextual AI

TL;DR:

• The FDA granted De Novo clearance to Spectral AI's DeepView — the first AI burn-wound assessment system, opening a brand-new device category for multispectral imaging in trauma and burn care.
• The pharma-AI operating model deepened in one week: Eli Lilly committed $500M to a Korean AI drug-discovery hub, QIAGEN tied up with NVIDIA on BioNeMo-powered target ID, and Bristol Myers Squibb put Claude in front of ~30,000 employees.
• Anthropic launched the Claude Compliance API with 28 enterprise security integrations (CrowdStrike, Microsoft Purview, Wiz, Okta, Zscaler, Cloudflare and more) — the missing governance layer hospitals and pharma IT have been waiting on.

Sources cited:

• GlobeNewswire
• Dong-A Science
• Digital Health News
• Digital Health News
• Gulf News
• BusinessWire
• HIT Consultant
• The Lancet Digital Health
• Help Net Security
• HeyGoTrade

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.